Αρχειοθήκη ιστολογίου

Κυριακή 30 Σεπτεμβρίου 2018

Phenotyping and long-term follow up of patients with hyper IgE syndrome

Publication date: Available online 29 September 2018

Source: Allergologia et Immunopathologia

Author(s): S. Alyasin, H. Esmaeilzadeh, N. Ebrahimi, S.H. Nabavizadeh, S. Kashef, E. Esmaeilzadeh, M. Babaei, R. Amin

Abstract
Introduction and objectives

Long-term follow up of patients with hyper IgE syndrome (HIES), as a primary immunodeficiency disorder, has been poorly investigated. This study describes common clinical and immunological features of patients with HIES in the last 10 years in Shiraz University of Medical Sciences, Shiraz, Iran.

Methods and patients

In this cross-sectional study, the symptoms and medical records of 18 patients, who were diagnosed with HIES, were observed. Genetic and immunologic study was also performed.

Results

Eighteen patients with the mean age of 13 years old were investigated. Ten patients were detected to have mutations in DOCK8 gene and autosomal recessive HIES (AR-HIES); and four patients were found with STAT3 mutation and autosomal dominant HIES (AD-HIES). So, 14 patients with known genetic results were considered for further data analysis. Food allergy, eczema, viral and skin infections were the major complications of AR-HIES patients. The major clinical complications of AD-HIES patients were pneumonia, skin infections and eczema. Food allergy and viral infection were significantly higher in DOCK8 deficient patients. The most common causes of hospitalization in both AR-HIES and AD-HIES patients were pneumonia, skin infections and sepsis. The most common cause of death was found to be sepsis.

Conclusions

AD-HIES and AR-HIES cannot be differentiated only based on the clinical presentations. Genetic features are also necessary for better diagnosis. This study, summarizing the clinical, immunological and genetic information of the patients with AD-HIES and AR-HIES, may open a way for better diagnosis and management of HIES.



https://ift.tt/2NOWVol

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου